awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q38525073-5A25A360-E481-455F-8EB3-45491B8CDE10
Q38525073-5A25A360-E481-455F-8EB3-45491B8CDE10
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38525073-5A25A360-E481-455F-8EB3-45491B8CDE10
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.
P2860
Q38525073-5A25A360-E481-455F-8EB3-45491B8CDE10
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38525073-5A25A360-E481-455F-8EB3-45491B8CDE10
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
cecb4aa7dee6a5c9309ad7ff25a16819bcf5a488
P2860
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).